In a 64-year-old man with a prostate-specific antigen (PSA) that increased from 3.6 ng/mL to 4.4 ng/mL last year and is now stable at 4.6 ng/mL with no symptoms, what is the appropriate management?

Management of Stable Elevated PSA in Asymptomatic 64-Year-Old Man

This patient requires urologic referral for consideration of prostate biopsy, along with a digital rectal examination (DRE), given his PSA above 4.0 ng/mL and the cumulative increase of 1.0 ng/mL over two years.

Rationale for Urologic Referral

The evidence provided focuses primarily on PSA monitoring in the context of testosterone replacement therapy, but the fundamental principles for PSA thresholds and biopsy indications apply to general screening populations. Multiple approaches exist for determining when to pursue prostate biopsy 1:

• PSA threshold approach: Biopsy or urologic referral when PSA rises above 4.0 ng/mL (several clinical trials)
• Combined threshold and velocity approach: Biopsy when PSA exceeds 4.0 ng/mL OR increases by more than 1.5 ng/mL over 2 years or more than 0.75 ng/mL/year over 2 years (Endocrine Society)

Analysis of This Patient's PSA Pattern

Your patient demonstrates:

• Current PSA: 4.6 ng/mL (above the traditional 4.0 ng/mL threshold)
• Total increase: 1.0 ng/mL over 2 years (from 3.6 to 4.6)
• Annual velocity: Approximately 0.5 ng/mL/year

While the PSA appears "stable" between the most recent two measurements (4.4 to 4.6), the cumulative two-year increase of 1.0 ng/mL combined with the absolute PSA above 4.0 ng/mL warrants evaluation 1.

Essential Next Steps

Immediate Actions:

1. Perform digital rectal examination - Any nodule, asymmetry, or areas of increased firmness would strengthen the indication for biopsy 1
2. Urologic referral for biopsy consideration given PSA >4.0 ng/mL 1

Important Caveats:

The absence of symptoms is not reassuring - most clinically significant prostate cancers are asymptomatic at diagnosis. The patient's lack of concern does not change the clinical indication for evaluation.

Age considerations: At 64 years old, this patient likely has sufficient life expectancy (>10 years) to benefit from early detection of clinically significant prostate cancer, making screening and follow-up appropriate.

PSA velocity context: While some guidelines suggest a yearly increase of 1.0 ng/mL or more as a trigger for biopsy 1, this patient's increase is just at that threshold over 2 years. However, the absolute PSA value above 4.0 ng/mL is itself an indication for urologic evaluation in most guideline frameworks 1.

Alternative Monitoring Approach (Less Preferred)

If the patient adamantly refuses urologic referral or biopsy consideration:

• Repeat PSA in 3-6 months 1
• Perform DRE at that visit
• If PSA increases by any amount or DRE becomes abnormal, urologic referral becomes mandatory
• Document the patient's informed refusal of recommended evaluation

However, this approach delays diagnosis of potentially curable cancer and is not the standard of care given current PSA levels.